University of Cape Town Faculty of Health Sciences
Cape Town, Western Cape, 7925, South Africa
Location status: Recruiting
Location contact
Anthea Van Wyk
CONTACT
Ernesta Meintjes, PhD
CONTACT
NCT Number: NCT04395196
Although the adverse effects associated with prenatal alcohol exposure (PAE) are well known, many women continue to drink heavily during pregnancy, putting their infants at risk for fetal alcohol spectrum disorders. Animal studies have shown that choline supplementation can mitigate effects of PAE on growth and development. Choline, an essential nutrient, serves as a methyl-group donor for DNA methylation and is a constituent of the neurotransmitter acetylcholine and a precursor to major components of cell membranes. In an R21 feasibility trial, 70 heavy drinkers were randomly assigned to receive a daily dose of 2g of choline or a placebo from initiation of antenatal care to delivery in Cape Town, South Africa, where the incidence of heavy drinking during pregnancy and fetal alcohol syndrome are among the highest in the world. When compared with infants in the placebo arm, infants in the choline-treated arm were more likely to meet criterion for eyeblink conditioning, demonstrated markedly better recognition memory on the Fagan Test of Infant Intelligence, which is known to have predictive validity for school-age IQ, and had better postnatal gains in weight and head circumference. Key features of this study included the higher choline dose (4.4 times adequate intake (AI), compared to 1.7-2.5 in previous human studies) and initiation of treatment early in pregnancy. We are now conducting a fully-powered, double-blind, randomized, placebo-controlled choline supplementation trial in heavy drinking pregnant women from a rural community in South Africa (1) to assess the effectiveness of maternal choline supplementation during pregnancy to mitigate effects of PAE on three primary outcomes: infant recognition memory and postnatal growth restriction (weight and head circumference); (2) to assess the efficacy of this supplementation for mitigating alcohol effects on the following secondary outcomes: infant eyeblink conditioning, postnatal length, and information processing speed; (3) to use innovative methods in causal inference analysis to examine protocol adherence as an important source of variation in treatment efficacy and to identify sociodemographic factors associated with non-compliance in order to facilitate implementation of the intervention protocol in clinical settings; and (4) in exploratory analyses, to examine whether maternal choline supplementation is particularly effective in women with lower dietary choline intake or poor nutritional status.
Interested in participating?
Request Info18 year–45 year
All sexes
Interventional
Phase 2
Cape Town, Western Cape, 7925, South Africa
Location status: Recruiting
Anthea Van Wyk
CONTACT
Ernesta Meintjes, PhD
CONTACT
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Provided in beverage form
Provided in beverage form
Time frame: 12 months
Novelty preference from the Fagan Test of Infant Intelligence
Time frame: 6.5 months
Time frame: 6.5 months
Time frame: 12 months
Processing speed on the Fagan Test of Infant Intelligence
Time frame: 6.5 months
Contact information is provided by the study sponsor or research team.
R. Colin Carter, MD, MMSc
CONTACT
Sandra W Jacobson, PhD
CONTACT
Wayne State University
Other
A Randomized, Double-Blind, Placebo-controlled Clinical Trial of Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure on Growth and Cognitive Development
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05534568
Alcohol Use Complicating Pregnancy, Childbirth, and the Puerperium, Alcohol Use Complicating Pregnancy, First Trimester
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT04332172
Alcohol-Induced Disorders, Alcohol-Related Disorders
Flint, Michigan, United States
View Trial DetailsNCT01149538
Alcohol Related Neurodevelopmental Disorder, Alcohol-Induced Disorders
Minneapolis, Minnesota, United States
View Trial DetailsNCT01911299
Alcohol-Induced Disorders, Alcohol-Related Disorders
San Diego, California, United States
View Trial Details